5 May 2026
Latham & Watkins Advises on Esperion’s US$1.1 Billion Acquisition by ARCHIMED
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ian Nussbaum Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Charles Ruck Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Patrick O'Neal | Latham & Watkins LLP | Associate | corporate | Not stated |
| Emily Johnson | Latham & Watkins LLP | Partner | finance | New York |
| Jenny Lyubomudrova | Latham & Watkins LLP | Associate | finance | Not stated |
| Sarah Lightdale | Latham & Watkins LLP | Partner | litigation | New York |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1.10bn (US$1.1 billion)
- What the figure measures
- Total transaction value
- Client
- Centerview PartnersOther
- Counterparties
- Esperion Therapeutics (Target)
ARCHIMED (Buy-side)